Climb Bio, Inc. — Director's Dealing 2022

Jun 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2022-05-19

Reporting Person: Dunn Judith (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-19	Stock Option (Right To Buy)	$3.46	A	10000	Acquired	2032-05-18	Common Stock (10000)	Direct

Footnotes

F1: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.